Loading clinical trials...

Comparing Aerobic to Resistance Training in Recovery From Cancer | Clinical Trials | Clareo Health

COMPLETEDNA

Comparing Aerobic to Resistance Training in Recovery From Cancer

NCT00237926•TriService Nursing Research Program

Summary

The purpose of this study is to compare the health outcomes of a 12-week exercise program focused on aerobic training (using a treadmill) to a 12-week exercise program focused on resistance training (using Thera-Bands) in sedentary patients within 6 months of completing treatment for cancer.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•have a biopsy-proven cancer diagnosis
•be within six months of having completed chemotherapy or radiation therapy for treatment for cancer as determined by the primary physician
•be ambulatory but sedentary (i. e., has not followed an exercise regimen of a minimum of 3 times per week for at least 20 minutes each session over the previous six weeks)
•have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 asymptomatic) or 1 (symptomatic, fully ambulatory)
•be at least 18 years old
•be able to read and speak English
•have a medical statement from either the patient's primary care provider or the primary oncologist indicating that participation in the program is not medically contraindicated

Exclusion Criteria

•following an exercise regimen a minimum of 3 times per week for at least 20 minutes each session within the previous 6 weeks
•bone or joint destruction that could be aggravated with exercise
•severe cognitive impairment identified by either the patient's medical care provider or by the study team
•neuropathy-sensory common toxicity criteria (CTC) grade 3 (sensory loss or paresthesia interfering with activities of daily living) or grade 4 (permanent sensory loss that interferes with function) peripheral neuropathy

Locations (1)

Brooke Army Medical Center

Fort Sam Houston, Texas, United States

Key Dates

Start Date

November 1, 2005

Primary Completion Date

March 1, 2008

Last Updated

August 1, 2008

Enrollment

ACTUAL participants

Conditions

Neoplasms

Interventions

Exercise

BEHAVIORAL

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITINGNA

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

NCT07159659

Thoracic Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 1, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comparing Aerobic to Resistance Training in Recovery From Cancer

Inclusion Criteria

Exclusion Criteria

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer